18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
11:29 , Jun 12, 2018 |  BC Extra  |  Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials...
19:02 , May 31, 2018 |  BC Innovations  |  Product R&D

Lilly’s new leaf

As Daniel Skovronsky takes the helm of Eli Lilly and Co.’s R&D business, his goal is to shake the pharma’s reputation as a fast-follower and instead advance first-in-class therapeutics with large effect sizes. To get...
18:23 , May 25, 2018 |  BC Week In Review  |  Clinical News

Janssen discontinues two Alzheimer's trials for BACE inhibitor

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said it is discontinuing two trials testing atabecestat (JNJ-54861911) to treat Alzheimer's disease after an evaluation showed the therapy led to elevated liver enzyme levels....
21:51 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Amgen, Novartis start Phase II to prevent AD

In August, Novartis AG (NYSE:NVS; SIX:NOVN), Amgen Inc. (NASDAQ:AMGN) and the Banner Alzheimer’s Institute (BAI) began the Phase II Alzheimer’s Prevention Initiative (API) Generation Study 2 to evaluate CNP520 to prevent Alzheimer’s disease. The double-blind,...
18:59 , Oct 27, 2017 |  BC Week In Review  |  Company News

Eisai exercises option for Biogen's anti-beta amyeloid mAb

Eisai Co. Ltd. (Tokyo:4523) exercised an option to co-develop and co-promote aducanumab (BIIB037) from Biogen Inc. (NASDAQ:BIIB). The industry has kept a close watch on the human recombinant anti-beta amyloid mAb after it became the...
22:09 , Oct 23, 2017 |  BC Extra  |  Company News

Eisai exercises option for Biogen’s anti-beta amyloid mAb

Eisai Co. Ltd. (Tokyo:4523) exercised an option to co-develop and co-promote aducanumab (BIIB037) from Biogen Inc. (NASDAQ:BIIB). The industry has kept a close watch on the human recombinant anti-beta amyloid mAb after it became the...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
01:09 , Feb 15, 2017 |  BC Extra  |  Clinical News

Merck stopping Phase III study of BACE inhibitor

Merck & Co. Inc. (NYSE:MRK) said it will halt the Phase II/III EPOCH study of verubecestat (MK-8931) to treat mild to moderate Alzheimer's disease based on findings of an external data monitoring committee (DMC), which...
03:37 , Dec 17, 2016 |  BioCentury  |  Product Development

Not dead yet

The amyloid hypothesis may not be dead, but positive Phase Ib data for Biogen Inc.’s aducanumab notwithstanding, the preponderance of evidence still suggests that attacking plaques is unlikely to be an effective intervention for Alzheimer’s...